What is Supernus Pharmaceuticals's ONAPGO — total revenues?

Supernus Pharmaceuticals (SUPN) reported ONAPGO — total revenues of $8.38M in Q1 2026.

What does ONAPGO — total revenues mean?

This metric represents the total gross revenue generated by the specific product line or business segment during the reporting period. It serves as a primary indicator of the segment's market adoption, commercial success, and contribution to the company's overall top-line financial performance.

Supernus Pharmaceuticals SUPN ONAPGO — Total revenues

Other product segments

Qelbree

$77.84M+20.2%

GOCOVRI

$35.24M+14.8%

Royalty, licensing, and other revenues

$29.31M+274%

Collaboration revenue (ZURZUVAE)

$27.64M—

Trokendi XR

$9.48M-26.0%

APOKYN

$7.73M-48.4%

Oxtellar XR

$7.42M-27.2%

Other

$4.67M-45.6%

Similar metrics at other companies

BCRXORLADEYO — Total revenues

$148.35M+10.5%

GHC

GHCGoods — Operating Revenues

$562.19M+8.4%

BMYOpdualag — Total Revenues

$295M+17.1%

BGCAPAC — Total revenues

$99.16M+31.1%

TDS

TDSTotal — Total operating revenues

$301.58M+6.1%

DBDAPAC — Total revenues (Note 17)

$73.4M+2.9%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's onapgo — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's ONAPGO — total revenues?: Supernus Pharmaceuticals (SUPN) reported ONAPGO — total revenues of $8.38M in Q1 2026.
What does ONAPGO — total revenues mean?: This metric represents the total gross revenue generated by the specific product line or business segment during the reporting period. It serves as a primary indicator of the segment's market adoption, commercial success, and contribution to the company's overall top-line financial performance.